When it comes to drug pricing, it’s time for patients to stand up and be counted! | By: Seth Ginsberg

Sep 9, 2016

Recently, the Institute for Clinical and Economic Review (ICER), released a scoping document outlining its intentions to evaluate the cost effectiveness of drugs used to treat the autoimmune disease Rheumatoid Arthritis (RA). ICER’s conclusions will be used by Medicare and insurance companies to determine coverage. In other words, the people who use your premiums pay for your prescription drugs are now deciding which drugs they will or won’t pay for, by taking ICER’s advice and using their reports as justification.

Read More ›

As Heart Disease Plagues the Black Community, America’s Access to Medicines May Be Headed for Crisis | By: Rev. Derek McCoy

Jul 13, 2016

By: Rev. Derek McCoy | The Orlando Advocate

Heart disease is the longstanding No. 1 killer of Americans, and the leading cause of death among Marylanders. While this silent killer devastates populations of all racial and ethnic groups, African-Americans are at the highest risk – deaths from heart disease among African Americans are 30 percent higher when compared to the White population.

Read More ›

Regerenon CEO Says Critique of the Company's New Cholesterol Lowering Therapy Was Non-Scientific

May 13, 2016

By: Mark Terry | BioSpace.com

Speaking yesterday at the Financial Times U.S. Healthcare & Life Sciences Summit, Leonard Schleifer, chief executive officer of Regeneron Pharmaceuticalssharply criticized the results of a report written by Boston-based Institute for Clinical and Economic Review (ICER) regarding its pricing for its new cholesterol medication. 

Read More ›